JP2022502498A - 血液疾患の低強度治療 - Google Patents

血液疾患の低強度治療 Download PDF

Info

Publication number
JP2022502498A
JP2022502498A JP2021540394A JP2021540394A JP2022502498A JP 2022502498 A JP2022502498 A JP 2022502498A JP 2021540394 A JP2021540394 A JP 2021540394A JP 2021540394 A JP2021540394 A JP 2021540394A JP 2022502498 A JP2022502498 A JP 2022502498A
Authority
JP
Japan
Prior art keywords
cpx
days
cytarabine
composition
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021540394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502498A5 (cg-RX-API-DMAC10.html
Inventor
チュン,ロナルド
ファダール,ステファン
ワン,チー
Original Assignee
セレーター ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレーター ファーマシューティカルズ インコーポレイテッド filed Critical セレーター ファーマシューティカルズ インコーポレイテッド
Publication of JP2022502498A publication Critical patent/JP2022502498A/ja
Publication of JP2022502498A5 publication Critical patent/JP2022502498A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021540394A 2018-09-25 2019-09-25 血液疾患の低強度治療 Pending JP2022502498A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862736393P 2018-09-25 2018-09-25
US62/736,393 2018-09-25
US201862772372P 2018-11-28 2018-11-28
US62/772,372 2018-11-28
PCT/US2019/052952 WO2020068979A1 (en) 2018-09-25 2019-09-25 Low-intensity treatment of hematological disorders

Publications (2)

Publication Number Publication Date
JP2022502498A true JP2022502498A (ja) 2022-01-11
JP2022502498A5 JP2022502498A5 (cg-RX-API-DMAC10.html) 2022-09-30

Family

ID=69950910

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540394A Pending JP2022502498A (ja) 2018-09-25 2019-09-25 血液疾患の低強度治療

Country Status (11)

Country Link
US (3) US20240252522A1 (cg-RX-API-DMAC10.html)
EP (1) EP3856198A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022502498A (cg-RX-API-DMAC10.html)
KR (1) KR20210065962A (cg-RX-API-DMAC10.html)
CN (1) CN113164502A (cg-RX-API-DMAC10.html)
AU (1) AU2019350759A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021005539A2 (cg-RX-API-DMAC10.html)
CA (1) CA3114002A1 (cg-RX-API-DMAC10.html)
IL (1) IL281729A (cg-RX-API-DMAC10.html)
MX (1) MX2021003527A (cg-RX-API-DMAC10.html)
WO (1) WO2020068979A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018009463A8 (pt) * 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
US20240252522A1 (en) * 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
CA3216716A1 (en) 2021-05-03 2022-11-10 Tim BERGBREDE Composition comprising an inhibitor of mitochondrial transcription

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519224A (ja) * 2007-02-16 2010-06-03 セラター・ファーマスーティカルズ・インコーポレーテッド 造血器癌および増殖性疾患の治療のための固定した薬物比

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1432403B1 (en) 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US20050118250A1 (en) 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
JP4972545B2 (ja) 2004-04-22 2012-07-11 セレーター ファーマスーティカルズ、インク. アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤
PT2768484T (pt) 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
BR112018009463A8 (pt) * 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
KR20230100748A (ko) * 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
CN110088166B (zh) 2016-12-01 2021-06-08 Jxtg能源株式会社 全芳香族液晶聚酯树脂
US20240252522A1 (en) * 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
US11980636B2 (en) * 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519224A (ja) * 2007-02-16 2010-06-03 セラター・ファーマスーティカルズ・インコーポレーテッド 造血器癌および増殖性疾患の治療のための固定した薬物比

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"History of Changes for Study: NCT03629171, Liposome-encapsulated Daunorubicin-Cytarabine and Venetoc", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6023036571, 4 September 2019 (2019-09-04), ISSN: 0005506736 *
ANDREW H. WEI ET AL., UPDATED SAFETY AND EFFICACY RESULTS OF PHASE 1/2 STUDY OF VENETOCLAX PLUS LOW-DOSE CYTARABINE IN TRE, JPN6023036572, 2017, pages 473, ISSN: 0005506735 *
BLOOD, vol. Vol.130(Suppl_1), JPN6023036570, 2017, pages 892, ISSN: 0005360626 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US12642811B2 (en) 2020-11-18 2026-06-02 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Also Published As

Publication number Publication date
CA3114002A1 (en) 2020-04-02
KR20210065962A (ko) 2021-06-04
AU2019350759A1 (en) 2021-04-22
US20210393665A1 (en) 2021-12-23
CN113164502A (zh) 2021-07-23
BR112021005539A2 (pt) 2021-06-29
EP3856198A1 (en) 2021-08-04
EP3856198A4 (en) 2022-06-22
IL281729A (en) 2021-05-31
US20260014183A1 (en) 2026-01-15
US12370207B2 (en) 2025-07-29
US20240252522A1 (en) 2024-08-01
WO2020068979A1 (en) 2020-04-02
MX2021003527A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
US20260014183A1 (en) Low-intensity treatment of hematological disorders
Isaacs et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin.
US9717731B2 (en) TEC family kinase inhibitor adjuvant therapy
Priestman Cancer chemotherapy in clinical practice
Von Minckwitz et al. Phase II study of gemcitabine in ovarian cancer
Bukowinski et al. Toxicity of cancer therapy in adolescents and young adults (AYAs)
DePillis et al. Mathematical model of colorectal cancer with monoclonal antibody treatments
Bello-Rivero et al. Development of a new formulation of interferons (HEBERPAG) for BCC treatment
Nogueira-Rodrigues et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer
Chiu et al. Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis
JP2016501208A (ja) ボラセルチブとの併用療法
US20240252526A1 (en) Treatment of hematological disorders
Bhutani et al. A clinical and correlative study of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for lenalidomide refractory multiple myeloma in first relapse
Fennelly et al. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: A phase I trial
CN121622884A (zh) 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
Fabbro et al. Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial
Smith et al. Differentiation therapy in poor risk myeloid malignancies: results of a dose finding study of the combination bryostatin-1 and GM-CSF
Maharaj et al. Molecular remission using personalized low-dose immunotherapy with minimal toxicities for poor prognosis hematological and solid tumor cancers
Drozd-Sokołowska et al. Outcomes of Jehovah’s Witnesses with hematological malignancies treated without transfusions—single center experience
AU2019390418A1 (en) Therapeutic methods and compositions for treating acute myeloid leukemia using devimistat
Noh et al. Optimal timing for the administration of capecitabine with preoperative chemoradiation for locally advanced rectal cancer
CN113925865A (zh) 安罗替尼联合免疫检查点抑制剂治疗晚期肺癌的增效组合药物
Westeel et al. Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: A multicenter phase II study
Inocencio et al. PCN86 Cost-Utility Analysis of Nilotinib Compared to Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Tan et al. A Phase II Trial of Gemcitabine, 5-Florouracil, and Radiation Therapy in Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma: Cancer and Leukemia Group B (CALGB)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250121